MDL | MFCD00233552 |
---|---|
Molecular Weight | 152.18 |
Molecular Formula | C5H4N4S |
SMILES | S=C1NC=NC2=C1NC=N2 |
6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive drug.
endogenous purines [1]
6-Mercaptopurine hydrate (6-MP) induces NR4A3 transcriptional activity 1.6- to 11-fold (P<0.01) in a dose-responsive manner. It is found that 6-Mercaptopurine hydrate leads to a dose-dependent increase in NR4A3 protein levels. 6-MP treatment increases cell surface GLUT4 in both basal cells 1.8- to 3.6-fold (P<0.01) and insulin-stimulated cells 2.9- to 4.4-fold (P<0.01) over that in controls. It is also found that 6-Mercaptopurine hydrate increases phospho-AS160 significantly in a dose-responsive manner under both basal and insulin-stimulated conditions [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In the fetal telencephalons of the 6-Mercaptopurine hydrate (6-MP)-treated group, the S phase cell population increases at 36 and 48 h and returns to the control level at 72 h after treatment. The G2/M phase cell population begins to increase at 24 h, peaks at 36 h, decreases at 48 h, and finally returnes to the control level at 72 h. On the other hand, the sub-G1 phase cell population (apoptotic cells) begins to increase at 36 h, peaks at 48 h, and then decreases at 72 h [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00003671 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
December 1998 | Phase 2 |
NCT00187005 | St. Jude Children´s Research Hospital |
Acute Lymphoblastic Leukemia
|
July 1998 | Phase 3 |
NCT02419469 | M.D. Anderson Cancer Center|Jazz Pharmaceuticals |
Leukemia|Precursor-B Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Lymphoma
|
November 13, 2015 | Phase 2 |
NCT02177071 | Groupe d´Etude Therapeutique des Affections Inflammatoires Digestives|Saint-Louis Hospital, Paris, France |
Crohn´s Disease
|
October 9, 2015 | Phase 4 |
NCT02143414 | National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia
|
January 12, 2015 | Phase 2 |
NCT01503632 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Acute Lymphoblastic Leukemia in Remission
|
February 21, 2012 | Phase 3 |
NCT00002744 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
May 1996 | Phase 3 |
NCT00005596 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
April 2000 | Phase 3 |
NCT00005945 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
June 2000 | Phase 3 |
NCT02003222 | National Cancer Institute (NCI)|Canadian Cancer Trials Group |
Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
December 23, 2013 | Phase 3 |
NCT00199095 | Johann Wolfgang Goethe University Hospital |
Adult Acute Lymphocytic Leukemia
|
February 1997 | Phase 4 |
NCT01432145 | University of Oxford |
Breast Cancer|Ovarian Cancer
|
May 2011 | Phase 2 |
NCT03020030 | Dana-Farber Cancer Institute|Servier |
Acute Lymphoblastic Leukemia, Pediatric
|
March 3, 2017 | Phase 3 |
NCT00061945 | National Cancer Institute (NCI) |
Acute Undifferentiated Leukemia|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|L1 Adult Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Adult Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia
|
June 2003 | Phase 1|Phase 2 |
NCT03007147 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia|T Acute Lymphoblastic Leukemia
|
July 28, 2017 | Phase 3 |
NCT00492856 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
June 2007 | Phase 3 |
NCT03518112 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Philadelphia Chromosome Negative|Recurrent B Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia
|
April 18, 2018 | Phase 2 |
NCT04043494 | University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany) |
Lymphoblastic Lymphoma, Childhood
|
August 23, 2019 | Phase 3 |
NCT02894645 | National University Hospital, Singapore |
Acute Lymphoblastic Leukemia (ALL)
|
October 2008 | Phase 4 |
NCT00707083 | Prince of Wales Hospital, Shatin, Hong Kong |
Leukemia
|
May 1, 2008 | Phase 3 |
NCT00962767 | Wyeth is now a wholly owned subsidiary of Pfizer |
Leukemia, Myelocytic, Acute
|
May 2002 | Phase 3 |
NCT00109837 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
April 2005 | Phase 2 |
NCT00526305 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
January 2000 | Phase 4 |
NCT00002766 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
March 1996 | Phase 3 |
NCT01700946 | St. Jude Children´s Research Hospital|Cookies for Kids´ Cancer|Assisi Foundation |
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood B-Lymphoblastic Lymphoma
|
April 15, 2013 | Phase 2 |
NCT02553460 | St. Jude Children´s Research Hospital|Gateway for Cancer Research|Baylor College of Medicine |
Acute Lymphoblastic Leukemia
|
January 29, 2016 | Phase 1|Phase 2 |
NCT01117441 | University Hospital Schleswig-Holstein|Deutsche Krebshilfe e.V., Bonn (Germany) |
Leukemia
|
June 2010 | Phase 3 |
NCT00526175 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
June 2001 | Phase 4 |
NCT01324336 | Children´s Mercy Hospital Kansas City|Midwest Cancer Alliance |
Acute Lymphoblastic Leukemia
|
July 2011 | |
NCT00550992 | Dutch Childhood Oncology Group|BFM Germany|CORS Monza Italy|Associazione Italiana Ematologia Oncologia Pediatrica|Australian and New Zealand Children´s Oncology Group|BFM Austria|CLCG France Belgium Portugal|COALL Germany|CPH, Czech republic|DFCI consortium USA|FRALLE France|Hong Kong|MD Anderson USA|NOPHO Scandinavian countries|PINDA, Chile|PPLLSG Poland|Seattle USA|SJCRH USA|UKCCSG United Kingdom |
Leukemia
|
January 2006 | Not Applicable |
NCT00002704 | National Cancer Institute (NCI) |
Leukemia
|
January 1996 | Phase 2 |
NCT05303792 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma
|
February 2023 | Phase 2 |
NCT02828358 | National Cancer Institute (NCI) |
Acute Leukemia of Ambiguous Lineage|B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia
|
March 27, 2017 | Phase 2 |
NCT01094613 | Teva GTC |
Crohn´s Disease
|
November 2010 | Phase 1|Phase 2 |
NCT02688140 | Technische Universität Dresden|Gruppo Italiano Malattie EMatologiche dell´Adulto|Groupe Francophone des Myelodysplasies|HOVON - Dutch Haemato-Oncology Association|Programa para el Tratamiento de Hemopatías Malignas|German Federal Ministry of Education and Research|Teva Pharmaceuticals Europe |
Acute Promyelocytic Leukemia
|
June 2016 | Phase 3 |
NCT00430118 | University Hospital Schleswig-Holstein |
Leukemia
|
July 2000 | Phase 3 |
NCT00268528 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Acute Lymphoblastic Leukemia in Remission
|
May 30, 2005 | |
NCT00287170 | Teva GTC |
Crohn´s Disease
|
July 2006 | Phase 1|Phase 2 |
NCT00004228 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
June 2000 | Phase 3 |
NCT00047268 | European Working Group of MDS in Childhood|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic+Myeloproliferative Neoplasms
|
July 1998 | Phase 3 |
NCT00558519 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia
|
March 12, 2008 | Phase 2 |
NCT00176462 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI) |
Acute Lymphocytic Leukemia
|
February 2001 | Phase 2 |
NCT00400946 | Dana-Farber Cancer Institute|National Cancer Institute (NCI) |
Drug+Agent Toxicity by Tissue+Organ|Leukemia
|
April 2005 | Phase 3 |
NCT00199069 | Johann Wolfgang Goethe University Hospital|Deutsche Krebshilfe e.V., Bonn (Germany) |
Adult Acute Lymphocytic Leukemia
|
April 1993 | Phase 4 |
NCT04216524 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Blastic Plasmacytoid Dendritic Cell Neoplasm
|
May 29, 2020 | Phase 2 |
NCT00002665 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia|Neutropenia|Thrombocytopenia
|
July 1995 | Phase 2 |
NCT00514982 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Hermanski-Pudlak Syndrome|Colitis|Cytokines|Lymphocytes|Drug Evaluation
|
August 7, 2007 | Phase 2 |
NCT01371630 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Burkitt-Like Lymphoma With 11q Aberration|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Burkitt Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Burkitt Lymphoma
|
August 26, 2011 | Phase 1|Phase 2 |
NCT00002785 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
July 1996 | Phase 2 |
NCT02036489 | PETHEMA Foundation |
Acute Lymphobkastic Leukemia
|
January 2008 | Phase 4 |
NCT01005758 | Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
January 2009 | Phase 2 |
NCT00005585 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
April 2000 | Phase 3 |
NCT03384654 | Janssen Research & Development, LLC |
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
May 14, 2018 | Phase 2 |
NCT00408005 | National Cancer Institute (NCI) |
T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma
|
January 22, 2007 | Phase 3 |
NCT00018954 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
October 1992 | Phase 2 |
NCT00973752 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Enzon Pharmaceuticals, Inc.|Genzyme, a Sanofi Company |
Acute Lymphoblastic Leukemia
|
August 2009 | Phase 2 |
NCT04546399 | National Cancer Institute (NCI) |
Down Syndrome|Recurrent B Acute Lymphoblastic Leukemia
|
December 4, 2020 | Phase 2 |
NCT02852694 | PIBD-Net|European Commission |
Crohn´s Disease
|
February 28, 2017 | Phase 4 |
NCT00187122 | St. Jude Children´s Research Hospital |
Lymphoblastic Lymphoma
|
March 1993 | Not Applicable |
NCT03488225 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia in Remission|B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
March 28, 2018 | Phase 2 |
NCT03286634 | National Hospital Organization Nagoya Medical Center |
Down Syndrome|Acute Lymphoblastic Leukemia|Childhood Cancer
|
April 18, 2017 | Phase 2 |
NCT02518750 | St. Jude Children´s Research Hospital|Novartis Pharmaceuticals|Spectrum Pharmaceuticals, Inc |
Acute Lymphoblastic Leukemia|Lymphoma, Non-Hodgkin´s|Leukemia, T-Cell|Leukemia, B-Cell
|
November 23, 2016 | Phase 2 |
NCT01190930 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Lymphoblastic Lymphoma|Ann Arbor Stage I B Lymphoblastic Lymphoma|Ann Arbor Stage II B Lymphoblastic Lymphoma|Childhood B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Childhood B Lymphoblastic Lymphoma|Down Syndrome|Hypodiploid B Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive
|
August 9, 2010 | Phase 3 |
NCT02303821 | Amgen|Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator|Innovative Therapies For Children with Cancer Consortium |
Acute Lymphoblastic Leukemia (ALL)
|
February 16, 2015 | Phase 1 |
NCT03571321 | University of Chicago|Incyte Corporation |
Acute Lymphoblastic Leukemia|ALL, Childhood|ALL
|
May 28, 2019 | Phase 1 |
NCT00002618 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
December 1994 | Phase 3 |
NCT00002701 | European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Malattie EMatologiche dell´Adulto|National Cancer Institute (NCI) |
Leukemia
|
October 1995 | Phase 3 |
NCT05032183 | M.D. Anderson Cancer Center |
Recurrent Adult Lymphoblastic Lymphoma|Recurrent B Acute Lymphoblastic Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Lymphoblastic Lymphoma|Refractory T Acute Lymphoblastic Leukemia
|
February 17, 2022 | Phase 1|Phase 2 |
NCT02660762 | Sun Yat-sen University |
Leukaemia,Lymphoblastic
|
January 2016 | Phase 2 |
NCT00199017 | Johann Wolfgang Goethe University Hospital |
Lymphoma, Lymphoblastic
|
April 2004 | Phase 4 |
NCT00494897 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
June 1996 | Phase 4 |
NCT00476190 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Boston Children´s Hospital|NCIC Clinical Trials Group |
Acute Lymphoblastic Leukemia
|
April 2007 | Phase 2 |
NCT02776605 | PETHEMA Foundation |
ALL
|
June 2016 | Phase 2 |
NCT04440267 | wang, jianxiang|Institute of Hematology & Blood Diseases Hospital |
Acute Leukemia of Ambiguous Lineage
|
June 20, 2020 | Phase 2 |
NCT00004688 | Emory University|FDA Office of Orphan Products Development |
Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Gliomas|Glioblastoma Multiforme|Recurrent Brain Tumor
|
August 1996 | Phase 2 |
NCT00003783 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
March 1999 | Phase 2 |
NCT00199056 | Johann Wolfgang Goethe University Hospital |
Adult Acute Lymphocytic Leukemia
|
October 1999 | Phase 4 |
NCT00275106 | Children´s Cancer and Leukaemia Group|European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma|National Cancer Institute (NCI) |
Lymphoma
|
September 2004 | Phase 3 |
NCT01230983 | Children´s Oncology Group|National Cancer Institute (NCI) |
Cardiac Toxicity|Leukemia|Lymphoma
|
June 1996 | Phase 3 |
NCT00648336 | Mylan Pharmaceuticals Inc|MylanPharma |
Healthy
|
November 2003 | Phase 1 |
NCT00002812 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
September 1996 | Phase 3 |
NCT03914625 | National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Down Syndrome
|
June 28, 2019 | Phase 3 |
NCT00557193 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Acute Undifferentiated Leukemia|Childhood T Acute Lymphoblastic Leukemia
|
January 14, 2008 | Phase 3 |
NCT02881086 | Goethe University |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma
|
August 2016 | Phase 3 |
NCT01358253 | Ruijin Hospital |
Acute Lymphoblastic Leukemia
|
December 2010 | Phase 4 |
NCT00136435 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Queen Elizabeth II Health Sciences Centre |
Acute Lymphoblastic Leukemia
|
June 2002 | Phase 2 |
NCT00866307 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
February 23, 2009 | Phase 1 |
NCT00551460 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
November 2007 | Phase 2 |
NCT01697020 | Nova Laboratories Limited |
Acute Lymphoblastic Leukemia
|
September 2012 | Phase 1 |
NCT01228331 | Universitätsklinikum Hamburg-Eppendorf |
Leukemia
|
October 2010 | Phase 2|Phase 3 |
NCT00096135 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
November 2004 | Not Applicable |
NCT04228393 | Wei Zhao|Institute of Hematology & Blood Diseases Hospital|Qianfoshan Hospital|Qilu Hospital of Shandong University|Children´s Hospital of Hebei Province|The Affiliated Hospital of Qingdao University|Shandong University |
Acute Lymphoblastic Leukemia, Pediatric
|
February 1, 2020 | Phase 2|Phase 3 |
NCT00764907 | University Hospital, Motol|National Cancer Institute (NCI) |
Leukemia
|
November 2002 | Phase 3 |
NCT00458848 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Leukemia
|
October 2004 | Phase 2 |
NCT02845882 | Children´s Cancer Group, China|Shanghai Children´s Medical Center|Tongji Hospital|West China Second University Hospital|Qilu Hospital of Shandong University|Tianjin Medical University Cancer Institute and Hospital|Children´s Hospital Of Soochow University|Nanjing Children´s Hospital|Xiangya Hospital of Central South University |
Lymphoblastic Lymphoma
|
January 2016 | Phase 3 |
NCT01920737 | Memorial Sloan Kettering Cancer Center|Shire|Duke University|Weill Medical College of Cornell University|Lehigh Valley Health Network |
Leukemia
|
August 2013 | Phase 2 |
NCT00866749 | M.D. Anderson Cancer Center |
Lymphoblastic Leukemia|Lymphoblastic Lymphoma
|
September 12, 2006 | Phase 2 |
NCT01256398 | National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
|
December 14, 2010 | Phase 2 |
NCT02419755 | St. Jude Children´s Research Hospital |
Mixed Lineage Acute Leukemia|Acute Myeloid Leukemia|Acute Lymphoid Leukemia
|
April 14, 2015 | Phase 2 |
NCT02723994 | Incyte Corporation|Children´s Oncology Group |
Leukemia
|
September 30, 2016 | Phase 2 |
NCT03959085 | Children´s Oncology Group|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Central Nervous System Leukemia|Mixed Phenotype Acute Leukemia|Testicular Leukemia
|
October 28, 2019 | Phase 3 |
NCT03920813 | Shandong University |
Acute Lymphoblastic Leukemia
|
January 2015 | Phase 4 |
NCT05157971 | City of Hope Medical Center|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|Ph-Like Acute Lymphoblastic Leukemia
|
March 17, 2022 | Phase 1 |
NCT03150693 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia
|
June 1, 2017 | Phase 3 |
NCT00003423 | United Kingdom Children´s Cancer Study Group|National Cancer Institute (NCI) |
Lymphoma
|
May 1995 | Phase 3 |
NCT02101853 | National Cancer Institute (NCI) |
Recurrent B Acute Lymphoblastic Leukemia
|
December 8, 2014 | Phase 3 |
NCT00198978 | Johann Wolfgang Goethe University Hospital |
Adult Acute Lymphocytic Leukemia
|
January 2003 | Phase 4 |
NCT00671034 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
July 21, 2008 | Phase 3 |
NCT00276601 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia
|
October 2004 | Phase 2 |
NCT01629628 | Tel-Aviv Sourasky Medical Center|Abbott |
Crohn Disease
|
July 2012 | Phase 3 |
NCT00199004 | Johann Wolfgang Goethe University Hospital |
Adult Acute Lymphocytic Leukemia
|
April 2004 | Phase 4 |
NCT00548431 | Rigshospitalet, Denmark |
Leukemia, Lymphocytic, Acute
|
December 2007 | Phase 2 |
NCT02205762 | North American Consortium for Histiocytosis|Histiocyte Society |
Langerhans Cell Histiocytosis
|
July 2014 | Phase 2|Phase 3 |
NCT00103285 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
April 11, 2005 | Phase 3 |
NCT00131027 | Japan Adult Leukemia Study Group |
Lymphoblastic Leukemia, Acute
|
September 2002 | Phase 3 |
NCT02420717 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent B Acute Lymphoblastic Leukemia|Recurrent Ph-Like Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Ph-Like Acute Lymphoblastic Leukemia
|
July 15, 2015 | Phase 2 |
NCT00198991 | Goethe University|Deutsche Krebshilfe e.V., Bonn (Germany)|German Federal Ministry of Education and Research |
Adult Acute Lymphocytic Leukemia
|
April 2003 | Phase 4 |
NCT01451515 | St. Jude Children´s Research Hospital|National University, Singapore |
Lymphoblastic Lymphoma
|
May 25, 2012 | Phase 2 |
NCT00774982 | Teva GTC |
Crohns Disease
|
December 2008 | Phase 1 |
NCT03553238 | Nanfang Hospital of Southern Medical University |
Leukemia, Acute|Leukemia, T Cell|Leukemia, Lymphoblastic
|
February 14, 2016 | Phase 2|Phase 3 |
NCT05192889 | St. Jude Children´s Research Hospital|AbbVie |
Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia
|
August 25, 2022 | Phase 1|Phase 2 |
NCT00002514 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Medical Research Council |
Leukemia
|
April 1993 | Phase 3 |
NCT00866918 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Acute Promyelocytic Leukemia With PML-RARA|Myeloid Neoplasm
|
March 9, 2009 | Phase 3 |
NCT00602134 | Roxane Laboratories|West-Ward Pharmaceutical |
Acute Lymphoblastic Leukemia
|
November 2002 | Not Applicable |
NCT02877303 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma
|
November 1, 2016 | Phase 2 |
NCT00015873 | Dutch Childhood Oncology Group |
Leukemia
|
May 1999 | Phase 3 |
NCT00022126 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
November 2002 | Phase 2 |
NCT01085617 | University College, London |
Leukemia|Mucositis|Oral Complications
|
December 2010 | Phase 3 |
NCT03643276 | Martin Schrappe|Deutsche Krebshilfe e.V., Bonn (Germany)|University Hospital Schleswig-Holstein |
Acute Lymphoblastic Leukemia, Pediatric
|
July 15, 2018 | Phase 3 |
NCT00187057 | St. Jude Children´s Research Hospital|Children´s Hospital of Philadelphia|National Cancer Institute (NCI) |
Ataxia-Telangiectasia
|
September 2002 | Not Applicable |
NCT00005603 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
March 2000 | Phase 3 |
NCT00002700 | European Organisation for Research and Treatment of Cancer - EORTC|Acute Leukemia French Association |
Leukemia|Lymphoma
|
August 1995 | Phase 3 |
NCT05506332 | University Hospital, Antwerp |
Acute Myeloid Leukemia, in Relapse|Acute Myeloid Leukemia Refractory
|
July 15, 2022 | Phase 1 |
NCT00262925 | National Cancer Institute (NCI) |
Recurrent Adult Acute Lymphoblastic Leukemia
|
June 2006 | Phase 2 |
NCT00089349 | National Cancer Institute (NCI) |
Recurrent Childhood Acute Lymphoblastic Leukemia
|
July 2004 | Phase 2 |
NCT00003728 | European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
December 1998 | Phase 3 |
NCT03370601 | University Hospital, Lille |
Inflammatory Bowel Diseases
|
January 3, 2017 | Not Applicable |
NCT00003650 | UNICANCER |
Lymphoma
|
February 1997 | Phase 3 |
NCT02883049 | National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|Central Nervous System Leukemia|Ph-Like Acute Lymphoblastic Leukemia|Testicular Leukemia
|
February 27, 2012 | Phase 3 |
NCT00381680 | Children´s Oncology Group|National Cancer Institute (NCI) |
B-cell Childhood Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia
|
March 2007 | Phase 3 |
NCT00002756 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
June 1996 | Phase 2 |
NCT01156883 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Leukemia
|
April 2010 | Not Applicable |
NCT00022737 | National Cancer Institute (NCI) |
Childhood Acute Lymphoblastic Leukemia in Remission|Recurrent Childhood Acute Lymphoblastic Leukemia
|
October 2002 | Phase 3 |
NCT00059839 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
November 2003 | Phase 3 |
NCT00016302 | National Cancer Institute (NCI) |
T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia
|
April 2001 | Not Applicable |
NCT00131053 | Japan Adult Leukemia Study Group |
Lymphoblastic Leukemia, Acute
|
September 2002 | Phase 2 |
NCT00003934 | National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Promyelocytic Leukemia (M3)|Childhood Acute Promyelocytic Leukemia (M3)|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
|
June 1999 | Phase 3 |
NCT03117751 | St. Jude Children´s Research Hospital|Incyte Corporation|Amgen|Servier |
Acute Lymphoblastic Leukemia|Acute Lymphoblastic Lymphoma
|
March 29, 2017 | Phase 2|Phase 3 |
NCT00343369 | Universitätsklinikum Hamburg-Eppendorf|National Cancer Institute (NCI) |
Leukemia
|
January 2003 | Not Applicable |
NCT00521950 | ZonMw: The Netherlands Organisation for Health Research and Development|Radboud University Medical Center |
Inflammatory Bowel Diseases|Crohn Disease|Ulcerative Colitis
|
September 2007 | Not Applicable |
NCT02611492 | Assistance Publique - Hôpitaux de Paris |
Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia
|
April 2016 | Phase 3 |
NCT00482833 | Gruppo Italiano Malattie EMatologiche dell´Adulto|Study Alliance Leukemia (SAL) Group |
Leukemia
|
August 2007 | Phase 3 |
NCT00003700 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia
|
January 1999 | Phase 2 |
NCT00187083 | St. Jude Children´s Research Hospital |
Acute Lymphoblastic Leukemia
|
February 1997 | Phase 3 |
NCT00019409 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Leukemia
|
October 1999 | Phase 3 |
NCT02910245 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|ZonMw: The Netherlands Organisation for Health Research and Development |
Colitis, Ulcerative
|
November 2016 | Phase 3 |
NCT00002531 | Johann Wolfgang Goethe University Hospital|National Cancer Institute (NCI) |
Leukemia
|
January 1993 | Phase 2 |
NCT00613457 | Associazione Italiana Ematologia Oncologia Pediatrica |
Leukemia
|
September 2000 | Phase 3 |
NCT00003437 | Medical Research Council|National Cancer Institute (NCI) |
Leukemia
|
January 1997 | Phase 3 |
NCT00720109 | National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
|
July 14, 2008 | Phase 2|Phase 3 |
NCT02413047 | Indiana University |
Inflammatory Bowel Disease|Ulcerative Colitis|Crohn´s Disease
|
May 2015 | Not Applicable |
NCT00501826 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma
|
July 11, 2007 | Phase 2 |
NCT00075725 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
December 29, 2003 | Phase 3 |
NCT00853008 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
January 2003 | Phase 4 |
NCT02112916 | National Cancer Institute (NCI) |
Adult T Acute Lymphoblastic Leukemia|Ann Arbor Stage II Adult Lymphoblastic Lymphoma|Ann Arbor Stage II Childhood Lymphoblastic Lymphoma|Ann Arbor Stage III Adult Lymphoblastic Lymphoma|Ann Arbor Stage III Childhood Lymphoblastic Lymphoma|Ann Arbor Stage IV Adult Lymphoblastic Lymphoma|Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma|Childhood T Acute Lymphoblastic Leukemia
|
September 30, 2014 | Phase 3 |
NCT02228772 | Massachusetts General Hospital|Millennium Pharmaceuticals, Inc. |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|B-cell Adult Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia
|
December 2014 | Phase 1 |
NCT02200978 | South China Children´s Leukemia Group |
Childhood Acute Promyelocytic Leukemia
|
September 2011 | Phase 4 |
NCT02523976 | Institute of Hematology & Blood Diseases Hospital |
Acute,Leukemia, Lymphoid
|
August 1, 2015 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
DMSO : 35.71 mg/mL ( 234.66 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 6.5712 mL | 32.8558 mL | 65.7117 mL |
5 mM | 1.3142 mL | 6.5712 mL | 13.1423 mL |
10 mM | 0.6571 mL | 3.2856 mL | 6.5712 mL |
Add each solvent one by one: 50% PEG300 >> 50% saline
Solubility: 3.33 mg/mL (21.88 mM); Suspended solution; Need ultrasonic
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (16.43 mM); Clear solution
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (16.43 mM); Clear solution